<DOC>
	<DOC>NCT01625000</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.</brief_summary>
	<brief_title>Safety and Efficacy of MP-214 in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Written informed consent obtained from the patient before the initiation of any studyspecific procedures Patients diagnosed with schizophrenia according to the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for schizophrenia Patients with normal physical examination, laboratory, vital signs, and/or electrocardiogram (ECG) Patients with a DSMIVTR diagnosis of schizoaffective disorder, schizophreniform disorder, other psychotic disorders other than schizophrenia, or bipolar I or II disorder</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Acute Schizophrenia</keyword>
	<keyword>Mental Disorder</keyword>
	<keyword>Psychotropic Drugs</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Central Nervous System Agents</keyword>
</DOC>